Mersana Therapeutics Stock Current Valuation
| MRSN Stock | USD 2.21 0.31 12.30% |
Valuation analysis of Mersana Therapeutics helps investors to measure Mersana Therapeutics' intrinsic value by examining its available valuation indicators, including the cash flow records, the balance sheet account changes and income statement patterns. As of the 16th of November 2024, Enterprise Value Over EBITDA is likely to drop to -0.81. In addition to that, Enterprise Value Multiple is likely to drop to -0.81. Fundamental drivers impacting Mersana Therapeutics' valuation include:
Price Book 36.6846 | Enterprise Value 178.7 M | Enterprise Value Ebitda (2.20) | Price Sales 8.936 | Enterprise Value Revenue 5.9694 |
Overvalued
Today
Please note that Mersana Therapeutics' price fluctuation is dangerous at this time. Calculation of the real value of Mersana Therapeutics is based on 3 months time horizon. Increasing Mersana Therapeutics' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since Mersana Therapeutics is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Mersana Stock. However, Mersana Therapeutics' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 2.21 | Real 2.13 | Target 2.0 | Hype 2.53 |
The intrinsic value of Mersana Therapeutics' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Mersana Therapeutics' stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Mersana Therapeutics helps investors to forecast how Mersana stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Mersana Therapeutics more accurately as focusing exclusively on Mersana Therapeutics' fundamentals will not take into account other important factors: Mersana Therapeutics Company Current Valuation Analysis
Mersana Therapeutics' Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Current Mersana Therapeutics Current Valuation | 178.71 M |
Most of Mersana Therapeutics' fundamental indicators, such as Current Valuation, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Mersana Therapeutics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Mersana Current Valuation Driver Correlations
Understanding the fundamental principles of building solid financial models for Mersana Therapeutics is extremely important. It helps to project a fair market value of Mersana Stock properly, considering its historical fundamentals such as Current Valuation. Since Mersana Therapeutics' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Mersana Therapeutics' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Mersana Therapeutics' interrelated accounts and indicators.
Click cells to compare fundamentals
Mersana Current Valuation Historical Pattern
Today, most investors in Mersana Therapeutics Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Mersana Therapeutics' growth ratios. Consistent increases or drops in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's current valuation growth rates may not be enough to decide which company is a better investment. That's why investors frequently use a static breakdown of Mersana Therapeutics current valuation as a starting point in their analysis.
Mersana Therapeutics Current Valuation |
| Timeline |
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
| Competition |
In accordance with the recently published financial statements, Mersana Therapeutics has a Current Valuation of 178.71 M. This is 98.76% lower than that of the Biotechnology sector and 96.15% lower than that of the Health Care industry. The current valuation for all United States stocks is 98.93% higher than that of the company.
Mersana Current Valuation Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Mersana Therapeutics' direct or indirect competition against its Current Valuation to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Mersana Therapeutics could also be used in its relative valuation, which is a method of valuing Mersana Therapeutics by comparing valuation metrics of similar companies.Mersana Therapeutics is currently under evaluation in current valuation category among its peers.
Mersana Therapeutics ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Mersana Therapeutics' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Mersana Therapeutics' managers, analysts, and investors.Environmental | Governance | Social |
Mersana Fundamentals
| Return On Equity | -2.13 | ||||
| Return On Asset | -0.26 | ||||
| Operating Margin | (11.10) % | ||||
| Current Valuation | 178.71 M | ||||
| Shares Outstanding | 122.67 M | ||||
| Shares Owned By Insiders | 1.26 % | ||||
| Shares Owned By Institutions | 93.84 % | ||||
| Number Of Shares Shorted | 9.87 M | ||||
| Price To Earning | (0.98) X | ||||
| Price To Book | 36.68 X | ||||
| Price To Sales | 8.94 X | ||||
| Revenue | 36.85 M | ||||
| Gross Profit | (146.8 M) | ||||
| EBITDA | (166.08 M) | ||||
| Net Income | (171.67 M) | ||||
| Cash And Equivalents | 225.13 M | ||||
| Cash Per Share | 2.32 X | ||||
| Total Debt | 33.83 M | ||||
| Debt To Equity | 0.28 % | ||||
| Current Ratio | 3.32 X | ||||
| Book Value Per Share | 0.31 X | ||||
| Cash Flow From Operations | (168.88 M) | ||||
| Short Ratio | 14.04 X | ||||
| Earnings Per Share | (0.85) X | ||||
| Target Price | 6.5 | ||||
| Number Of Employees | 123 | ||||
| Beta | 1.48 | ||||
| Market Capitalization | 322.64 M | ||||
| Total Asset | 226.06 M | ||||
| Retained Earnings | (826.36 M) | ||||
| Working Capital | 150.42 M | ||||
| Current Asset | 71.4 M | ||||
| Current Liabilities | 51.32 M | ||||
| Net Asset | 226.06 M |
About Mersana Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Mersana Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Mersana Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Mersana Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Pair Trading with Mersana Therapeutics
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Mersana Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Mersana Therapeutics will appreciate offsetting losses from the drop in the long position's value.Moving together with Mersana Stock
Moving against Mersana Stock
| 0.87 | VALN | Valneva SE ADR | PairCorr |
| 0.57 | VCNX | Vaccinex | PairCorr |
| 0.53 | ME | 23Andme Holding | PairCorr |
| 0.53 | DTIL | Precision BioSciences | PairCorr |
| 0.49 | DRMA | Dermata Therapeutics | PairCorr |
The ability to find closely correlated positions to Mersana Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Mersana Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Mersana Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Mersana Therapeutics to buy it.
The correlation of Mersana Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Mersana Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Mersana Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Mersana Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Mersana Therapeutics Piotroski F Score and Mersana Therapeutics Altman Z Score analysis. To learn how to invest in Mersana Stock, please use our How to Invest in Mersana Therapeutics guide.You can also try the Fundamentals Comparison module to compare fundamentals across multiple equities to find investing opportunities.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Mersana Therapeutics. If investors know Mersana will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Mersana Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.85) | Revenue Per Share 0.247 | Quarterly Revenue Growth (0.79) | Return On Assets (0.26) | Return On Equity (2.13) |
The market value of Mersana Therapeutics is measured differently than its book value, which is the value of Mersana that is recorded on the company's balance sheet. Investors also form their own opinion of Mersana Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Mersana Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Mersana Therapeutics' market value can be influenced by many factors that don't directly affect Mersana Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Mersana Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Mersana Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Mersana Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.